Impact on Risk Stratification of Overlap Syndrome Phenotype (Brugada and Long QT Type 3) in Patients With E1784K Mutation in SCN5A

Status: Completed
Study Type: Observational
SUMMARY

In patients expressing the SCN5A-E1784K mutation (Glu1784Lys), cardiovascular risk is difficult to define as the stratification of these patients is challenging. From our experience, major cardiovascular events (MCE) tend to occur more frequently in patients expressing overlap syndrome phenotype (Brugada syndrome and Long QT syndrome type 3)than in patients expressing a single phenotype (whether Brugada syndrome or Long QT syndrome type 3). This trials is led on the impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A ( RISKOVER )

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
View:

• genotype E1784K (glu1784lys) in SCN5A gene

Time Frame
Start Date: 2022-04-05
Completion Date: 2024-03-20
Participants
Target number of participants: 47
Treatments
E1784K (glu1784lys) in SCN5A expressing either Long QT syndrome type 3 or Brugada syndrome
E1784K (glu1784lys) in SCN5A expressing both syndromes (Long QT syndrome and Brugada syndrome)
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier Universitaire de la Réunion

This content was sourced from clinicaltrials.gov